The present invention relates to a cosmetic composition comprising a branch portion extract comprising at least approximately 50 wt % of polyphenols and less than approximately 10 wt % of terpenes, relative to the total weight of the extract, in a cosmetically acceptable medium. The invention also relates to the use of such a cosmetic composition for combatting the signs of skin ageing and/or for reinforcing the skin barrier.
A61K 8/9767 - Pinaceae [famille du pin], p. ex. pin ou cèdre
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
The present invention relates to a sublingual composition comprising a part of branch extract, preferably from at least one resinous tree comprising at least about 50 % by weight of polyphenols and less than about 10 % by weight of terpenes, relative to the total weight of the extract. The present invention further relates to the non-therapeutic uses of such sublingual composition for improving the respiratory wellness, relieving joint pain and/or muscular pain and cramps and/or improving endurance, and improving libido and/or fertility.
A61K 36/15 - Pinaceae (famille du pin), p. ex. pin ou cèdre
A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.
A61K 31/545 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
4.
NEW DERIVATIVES OF CEPHALOSPORIN FOR TREATING CANCER
The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.
A61K 31/545 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine
The present invention relates to a knot-wood extract comprising at least one lignan selected from the list comprising (-)-hydroxymatairesinol (two epimers; 7S, 8R, 8'R and 7R, 8R, 8'R), (-)(7S, 8R, 8'R)-hydroxymatairesinol, (+)-lariciresinol, (-)-secoisolariciresinol, liovil and any epimers thereof. The present invention also relates to a method of activating a β2 adrenergic receptor, comprising administering an effective amount of a knot-wood extract of the invention or of at least one lignan selected from the list comprising (-)-hydroxymatairesinol (two epimers; 7S, 8R, 8'R and 7R, 8R, 8'R), (-)(7S, 8R, 8'R)-hydroxymatairesinol, (+)-lariciresinol, (-)-secoisolariciresinol, liovil and any epimers thereof. The present invention also relates to a method of treating a β2 adrenergic receptor related disease in a subject in need thereof, comprising administering to the subject an effective amount of a knot- wood extract of the invention or of at least one lignan selected from the list comprising (-)-hydroxymatairesinol (two epimers; 7S, 8R, 8'R and 7R, 8R, 8'R), (-)(7S, 8R, 8'R)-hydroxymatairesinol, (+)-lariciresinol, (-)-secoisolariciresinol, liovil and any epimers thereof.
A61K 36/76 - Salicaceae (famille du saule), p. ex. peuplier
A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide
A61K 36/15 - Pinaceae (famille du pin), p. ex. pin ou cèdre
The present invention relates to a compound for use in the prevention and/or treatment of a disease selected from a neurodegenerative disease, especially Alzheimer disease, and a disease, disorder or condition involving an activation of phosphodiesterase-4 (PDE4), wherein said compound is of general formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X and Z each independently represent CH or N; Y represents O or S; R1, R2 and R3 may be the same or different and represent a hydrogen atom, a halogen atom, hydroxyl, nitro, cyano, amino, amido, carbamate, alkyl, alkenyl, alkynyl, alkoxy, heterocyclic, carbocyclic, alkylthio, carboxy, or alkoxycarbonyl; R4 represent a hydrogen atom; R5, R6, R7 and R8 may be the same or different and represent a hydrogen atom, halogen atom, hydroxyl, nitro, amino, alkyl, alkoxy, alkylthio, or tnfluoromethyl; R9 and R10 may be the same or different and represent a hydrogen atom, alkyl, alkylcarbonyl, heterocyclic, carbocyclic, ON02, or OS02R wherein R is hydroxyl, alkyl, carbocyclic; and R11 represents an alkyl, alkenyl, alkynyl, alkoxy, akoxycarbonyl, amino, amido, heterocyclic, carbocyclic, or optionally substituted azolyl.
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
brevets
